MRTX inventory crashes after mid-stage information for KRAS inhibitor in lung most cancers (NASDAQ:MRTX)
wildpixel/iStock through Getty Photos Mirati Therapeutics (NASDAQ:MRTX) plunged 23% within the post-market Thursday after the clinical-stage oncology firm shared trial ...